Bausch & Lomb Reports Tomorrow With Analysts Already Resigned to Single-Digit Growth

Bausch + Lomb Corporation (NYSE: BLCO) reports first-quarter 2026 earnings tomorrow morning before the bell, with analysts expecting $0.06 per share on revenue of approximately $1.21 billion. The eyecare company enters the print with momentum from its blockbuster dry-eye drug MIEBO and a recovering surgical business, but investors will scrutinize whether management can sustain margin expansion and deliver on its ambitious full-year guidance. After a mixed Q4 that saw a revenue beat but an EPS miss, the question is whether BLCO can prove its turnaround story has staying power.

Part 1: Earnings Preview

Bausch + Lomb operates as a global eye health company across three segments: Vision Care (contact lenses and lens care products), Pharmaceuticals (prescription eye drops and treatments), and Surgical (cataract and retinal surgery equipment and intraocular lenses). The company serves both consumer and professional markets with a portfolio spanning daily disposable contact lenses, blockbuster drugs like MIEBO for dry eye, and premium surgical technologies.

For the quarter ending March 2026, Wall Street expects $0.06 per share from five analysts, with estimates ranging from $0.02 to $0.14. The most recent quarter (Q4 2025) delivered $0.32 per share, though that missed the $0.35 consensus by three cents. Year-over-year, the Q1 2026 estimate represents a dramatic turnaround from the $-0.07 loss reported in Q1 2025, implying +185.71% growth and marking a potential inflection point in profitability.

Three key themes define this earnings story:

MIEBO's Blockbuster Trajectory: The dry-eye treatment posted $316 million in full-year 2025 revenue with $112 million in Q4 alone, reaching 2 million prescriptions and prompting management to raise peak sales potential above $600 million. Investors will watch whether Q1 prescription trends support this aggressive outlook and whether the drug can sustain its momentum as competition intensifies in the dry-eye market.

Surgical Business Recovery: Following the enVista IOL recall, the surgical segment returned to prior market levels ahead of plan, with premium intraocular lenses up approximately 20% in Q4. The question is whether this recovery can accelerate in Q1 and drive the higher-margin product mix that management needs to hit its full-year Adjusted EBITDA target of $1.0–$1.05 billion.

2026 Guidance Credibility: Management projects full-year revenue of $5.375–$5.475 billion (5%–7% constant-currency growth) with continued margin expansion. After the Q4 EPS miss, investors need to see Q1 execution that validates these targets and demonstrates the company can convert top-line growth into bottom-line leverage.

Analyst commentary ahead of the release reflects cautious optimism. Citigroup upgraded BLCO to Buy in December with a $20 target, citing the surgical recovery and MIEBO momentum. However, the majority of the Street remains on the sidelines—nine of 14 analysts rate the stock Hold—suggesting skepticism about whether the company can consistently deliver on its multi-year margin expansion roadmap. Goldman Sachs maintains a Neutral rating with a $19 target, noting that while product momentum is real, execution risk remains elevated given the company's history of missing EPS estimates.

Part 2: Historical Earnings Performance

Bausch + Lomb's earnings track record over the past four quarters reveals an inconsistent pattern that has kept investors cautious. The company posted two beats and two misses, with surprise magnitudes ranging from a -333.33% miss in Q1 2025 to a +16.67% beat in Q2 2025. The most recent quarter (Q4 2025) delivered a -8.57% miss at $0.32 versus the $0.35 consensus, breaking a two-quarter streak of modest beats.

The trend shows improvement from the disastrous Q1 2025 loss of $-0.07 (against a $0.03 estimate) through a recovery arc that peaked at $0.32 in Q4 2025. However, the inability to consistently meet or exceed expectations—particularly the Q4 miss after two consecutive beats—raises questions about earnings visibility and management's ability to guide accurately. The year-over-year comparison for the upcoming quarter is favorable given the easy comp against last year's loss, but investors will need to see not just a beat but also confidence-building guidance to shift sentiment.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Bausch + Lomb typically reports before market open, meaning Day 0 captures the first reaction session and Day +1 reflects follow-through trading.

Historical price behavior shows significant volatility on earnings day with an average absolute Day 0 move of 4.21% and intraday range of 7.22%. The most dramatic reaction came on April 30, 2025, when the stock plunged -15.74% on the day with an 11.30% intraday range, likely reflecting the Q1 2025 loss. More recently, the February 2026 report produced a muted -0.34% Day 0 move despite the EPS miss, suggesting the market may have already priced in disappointment.

Day +1 follow-through is more subdued, averaging 1.17% with a 4.23% range, indicating most of the price discovery happens in the initial session. Investors should prepare for a potential 4%–5% swing tomorrow based on whether the company beats or misses the $0.06 consensus, with particular sensitivity to guidance commentary given the stock's history of outsized moves when results disappoint materially.

Part 2.2: Options Market Expected Move

The options market is pricing a 4.60% expected move through the May 15 expiration (17 days out), slightly above the historical Day 0 average of 4.21% but well below the 7.22% average intraday range. This suggests options traders are anticipating moderate volatility, though the elevated implied volatility of 96.22% indicates uncertainty remains high heading into the print.

Part 3: What Analysts Are Saying

Analyst sentiment on Bausch + Lomb remains cautious, with the consensus rating at 3.43 (Hold) across 14 analysts. The breakdown shows 3 Strong Buys, 1 Moderate Buy, 9 Holds, 1 Moderate Sell, and 0 Strong Sells—a distribution that reflects skepticism about the stock's near-term upside despite improving fundamentals. The average price target of $18.33 implies 16.6% upside from the current price of $15.72, with a wide range from a $15.00 low to a $21.00 high target.

Sentiment has remained unchanged over the past month, with rating counts and the average recommendation holding steady at 3.43. This stability suggests analysts are in wait-and-see mode ahead of earnings, unwilling to upgrade until the company demonstrates it can consistently meet expectations and validate its full-year guidance. The December upgrade from Citigroup to Buy ($20 target) provided a brief catalyst, but the broader Street has not followed suit, keeping the majority of ratings at Hold.

The $18.33 consensus target sits roughly in line with Goldman Sachs' $19 Neutral rating and below Citigroup's $20 Buy target, indicating the Street sees fair value in the high teens but needs proof of execution before getting more aggressive. With the stock trading at $15.72, investors have modest upside to the average target, but the wide estimate range ($15–$21) reflects significant disagreement about the company's ability to deliver on its margin expansion story and MIEBO's peak sales potential.

Part 4: Technical Picture

Bausch + Lomb enters earnings with a deteriorating technical setup that has turned increasingly bearish over the past month. The Barchart Technical Opinion currently reads 40% Sell, a significant weakening from 24% Sell one week ago and 24% Sell one month ago, indicating accelerating downside momentum as the stock approaches the print.

Timeframe Analysis:

• Short-term (50% Sell): Moderate sell signal indicates near-term momentum has turned negative heading into earnings
• Medium-term (Hold): Neutral reading suggests the intermediate trend remains in consolidation mode
• Long-term (50% Sell): Moderate sell signal reflects persistent weakness in the longer-term trend structure

Trend Characteristics: The combination of Weak strength and Average direction suggests the stock is in a fragile technical environment with limited conviction in either direction, making it vulnerable to sharp moves on earnings surprises.

The stock is trading at $15.72, positioned below all major moving averages: the 5-day ($15.85), 10-day ($16.23), 20-day ($16.33), 50-day ($16.76), 100-day ($16.87), and 200-day ($15.87). This universal resistance overhead creates a technically challenging setup, with the nearest support at the 200-day average just 15 cents below the current price.

The technical picture heading into earnings is cautionary, with the stock trapped below a wall of moving average resistance and deteriorating momentum across all timeframes. The 200-day moving average at $15.87 represents critical support—a break below on a disappointing print could trigger further selling toward the $15.00 level (the low end of analyst targets). Conversely, a strong beat with confidence-building guidance would need to reclaim the 20-day average at $16.33 to shift the technical tone, with the 50-day at $16.76 serving as the next resistance hurdle. The weak technical setup amplifies downside risk if the company misses or guides cautiously, while limiting upside unless results materially exceed expectations.